Clinical Trial Update: A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together [Phase 1]

View source ↗

Summary

Pfizer-sponsored Phase 1 trial completed to identify the best dosing combination of sunitinib (SU011248) and capecitabine in patients with solid tumors and brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neoplasms
• Solid Tumors

Drugs mentioned

• Sutent (sunitinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Pfizer | Conditions: Solid Tumors, Breast Cancer | Phase 1 | Status: COMPLETED